Click on links on the left for bibliographic information related to
a specific research area
2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin
Kidney J 5,
17-27,
2012
GPER regulates endothelin-dependent vascular tone
and intracellular calcium
M.R.
Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R.
Prossnitz
Life
Sci epub
Feb 2, 2012
Endothelin receptor antagonists in cardiovascular
medicine: Challenges and opportunities
M.
Barton
In:
Translational Vascular Medicine (D.
Abraham, Ed) Springer London, 231-259, 2012
Deletion of the G protein-coupled estrogen receptor
increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hatheyway, N.L.
Kanagy, M.K. Waker, M. Barton, E.R. Prossnitz
Hypertension
59,
507-512, 2012
Childhood obesity: a life-long health
risk
M. Barton
Acta
Pharmacol Sin 33,
189-193, 2012
Obesity and risk of vascular disease: Importance of
endothelium-dependent vasoconstriction
M.
Barton, O. Baretella, M.R. Meyer
Br
J Pharmacol 165,
591-602, 2012
2011
The G protein-coupled estrogen receptor GPER in
physiology and disease
E.R. Prossnitz, M. Barton
Nature
Rev Endocrinol 7,
715-726, 2011
Endothelin in renal physiology and
disease
Contrib
Nephrol 172
(M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266,
2011
The G protein-coupled estrogen receptor GPER/GPR30
as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton
Vascul
Pharmacol 55,
17-25, 2011
Endothelin antagonists in clinical trials: Lessons
learned
M. Barton, D.E. Kohan
Contrib
Nephrol 172,
255-260, 2011
Endothelin and podocyte injury in chronic kidney
disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib
Nephrol 172,
120-138, 2011
Endothelin antagonism and reversal of proteinuric
renal disease in humans
M. Barton
Contrib
Nephrol 172,
210-222, 2011
Obesity, insulin resistance and diabetes: sex
differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M.
Barton
Acta
Physiol (Oxf) 203,
259-269, 2011
GPER/GPR30 and regulation of vascular tone and blood
pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol
Endocr Metab Agents Med Chem 4,
255-261, 2011
Estrogen-independent activation of estrogen
receptors
M.
Barton, M.R. Meyer, E.R. Prossnitz
Hypertension
57,
1056-1057, 2011
The discovery of endothelium-dependent contraction:
the legacy of Paul M. Vanhoutte
M. Barton
Pharmacol
Res 63,
455-462, 2011
2010
Therapeutic potential of endothelin receptor
antagonists for chronic proteinuric renal disease in
humans
M. Barton
Biochim
Biophys Acta 1802,
1203-1213, 2010
Obesity and aging: determinants of endothelial cell
dysfunction and atherosclerosis
M. Barton
Pflügers
Arch Eur J Physiol 460,
825-837, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu
Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss
Medical Forum 10,
358-362, 2010
Anti-inflammatory effects of endothelin receptor
antagonists and their importance for treating human
disease
M. Barton, P.C. Nett, K. Amann, M.M.
Teixeira
Front
Cardiovasc Drug Discov 1,
236-258, 2010
Dilation of epicardial coronary arteries by the G
protein-coupled estrogen receptor agonists G-1 and ICI
182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M.
Barton
Pharmacology
86,
58-64, 2010
Lung cancer and hormone replacement
therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R.
Prossnitz
Lancet
375,
117-118, 2010
2009
Postmenopausal hypertension: Mechanisms and
therapy
M. Barton, M.R. Meyer
Hypertension
54,
11-18, 2009
ERα, ERβ, and gpER: novel aspects of estrogen
receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83,
605-610, 2009
Non-genomic regulation of vascular cell function and
growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M.
Barton
Mol
Cell Endocrinol 308,
9-16, 2009
Signaling, physiological functions and clinical
relevance of the G protein-coupled estrogen receptor
GPER
E.R. Prossnitz, M. Barton
Prostaglandins
Other Lipid Mediat 89,
89-97, 2009
Regulatory role of G protein coupled estrogen
receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C.
Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut,
R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M.
Genoni, D.J. Clegg, N.J. Dun,
T.C. Resta, E.R. Prossnitz, M. Barton
Circ
Res 104,
288-291, 2009
Getting radical about obesity: new links between fat
and heart disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler
Thromb Vasc Biol 29,
447-448, 2009
Morbus Addison bei metastasierendem
Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B.
Senn
Swiss
Medical Forum 9,
487-488, 2009
2008
Endothelin - Twenty years from discovery to
therapy
M. Barton, M. Yanagisawa
Can
J Physiol Pharmacol 86,
485-498, 2008
Reversal of proteinic renal disease and the emerging
role of endothelin
M. Barton
Nature
Clin Pract Nephrol 4,
490-498, 2008
Need for research on estrogen function: importance
for postmenopausal hormone therapy and
atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend
Med 5
(Suppl. A), S19-S33, 2008
Regional heterogeneity of functional changes in
conduit arteries after high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M.
Barton
Obesity
(Silver Spring) 16,
743-748, 2008
Schwere Verhaltensstörung mit organischer
Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I.
Bopp-Kistler
Praxis
(Bern 1994) 97,
1137-1141, 2008
Fat intake and cardiovascular
response
M.
Damjanovic, M. Barton
Curr
Hypertens Rep 10,
25-31 2008
2007
Inflammation and
atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ
Res 101,
750-751, 2007
Hormone replacement therapy and atherosclerosis in
postmenopausal women: does aging limit therapeutic
benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler
Thromb Vasc Biol 27,
1669-1672, 2007
WISDOM trial, postmenopausal hormone replacement and
cardiovascular events: Why it is still not wise to use equine
estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br
Med J Rapid
Response, e-pub August 28, 2007
Atherosklerotische Gefässerkrankungen und
Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher
Lebenserwartung
und Übergewicht für die
Klinik
M. Husmann, M. Keller, M. Barton
Swiss
Medical Forum 50,
1008-1011, 2007
Distinct roles of estrogen receptors
α
and
β
mediating acute vasodilatation of epicardial
coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R.
Minotti, M. Barton
Hypertension
49,
1364-1370, 2007
Differential effects of 17β-estradiol on function
and expression of estrogen receptor α, estrogen receptor β, and
GPR30 in arteries and veins of patients with
atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H.
Nguyen, A. Heigl, M. Lachat, M. Genoni, M.
Barton
Hypertension
49,
1358-1363, 2007
Effects of obesity on mortality in patients with
unstable angina or non ST-elevation myocardial
infarction
M. Barton, M. Husmann
Eur
Heart J 28,
2950, 2007
Impaired vascular function in normoglycemic mice
prone to autoimmune diabetes: Role of nitric
oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann,
L.M. Terracciano, M. Barton
Eur
J Pharmacol 557,161-167,
2007
Artériopathies athérosclérotique et monoxyde d’azote
(NO) : l’importance clinique d’une espérance de vie plus
longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum
Médical Suisse 50,
1008-1011, 2007
Vaskuläre
Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M.
Barton
Dtsch
Med Wochensch 132,
20, 2007
Endothelin stimulates vascular hydroxyl radical
formation: effect of obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K.
Baumann, M. Barton
Am
J Physiol Regul Integr Comp Physiol 293,
R2218-R2224, 2007
Fat intake modifies vascular responsiveness and
receptor expression of vasoconstrictors: Implications for
diet-induced obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R.
Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc
Res 73,
368-375, 2007
Therapeutic potential of direct thrombin inhibitors
for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert
Opin Investig Drugs 16,
563-567, 2007
Oral direct thrombin inhibitors and
atherosclerosis
M. Husmann, M. Barton
International
Atherosclerosis Society ,
e-pub Sept 3, 2007
Antioxidant activity and sex differences of acute
vascular effects of amiodarone in advanced
atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha,
W. Jochum, A.L. Mundy, M. Barton
J
Cardiovasc Pharmacol 50,
578-584, 2007
2006
Gender differences of cardiovascular disease: new
perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension
47,
1019-26, 2006
Transcriptional regulation of vascular bone
morphogenetic protein by endothelin receptors in early autoimmune
diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L.
Tornillo, L.M. Terraciano, M. Barton
Life
Sci 78,
2213-2218, 2006
Recent developments on endothelin antagonists as
immunomodulatory drugs - from infection to transplantation
medicine.
P.C. Nett, M.M. Teixeira, D. Candinas, M.
Barton
Recent
Pat Cardiovasc Drug Discov 1,
233-244, 2006
Role of endothelin receptors for renal protection
and survival in hypertension. Waiting for clinical
trials
M. Barton, J.J. Mullins, M.A. Bailey, M.
Kretzler
Hypertension
48,
834-837, 2006
Endothelin ETA
receptor blockade with darusentan increases sodium
and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R.
Hofmann-Lehmann, K. Baumann, M. Barton
J
Cardiovasc Pharmacol 47,
456-462, 2006
Beneficial cardiovascular effects of endothelin
ETA
receptor blockade in established long-term heart
failure after myocardial infarction
D. Vetter, S.G. Shaw, R.P. Brandes, K. Münter, W. Vetter, M.
Barton
Exp
Biol Med (Maywood) 231,
857-60, 2006
Upregulation of endothelin converting enzyme-1 in
host liver during chronic cardiac allograft
rejection
T. Lattmann, J. Ortmann, S. Horber, S.G. Shaw, M. Hein, M.
Barton
Exp
Biol Med (Maywood) 231,
899-901, 2006
Long-term effects of endovascular angioplasty on
orthostatic vasocutaneous autoregulation in patients with
peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R.
Amann-Vesti
J
Vasc Surg 44,
993-997, 2006
Downregulation of renal endothelin-converting enzyme
2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo,
L.M. Terraciano, M. Barton
Exp
Biol Med (Maywood) 231,
1030-1033, 2006
Early aging and anatomic heterogeneity determine
cyclooxygenase-mediated vasoconstriction to angiotensin II in
mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J
Cardiovasc Pharmacol 48,
30-33, 2006
Rapid endocytosis of copper-zinc superoxide
dismutase into human endothelial cells: role for its vascular
activity
E.R. Waelti, M. Barton
Pharmacology
78,
198-201, 2006
Upregulation of endothelin receptor B in human
endothelial cells by low-density
lipoproteins
G. Muller, R.A. Catar, B. Niemann, M. Barton, L. Kneels, M. Wendel,
H. Morawietz
Exp
Biol Med (Maywood) 231,
766-771, 2006
Life
Sci 78,
2213-2218, 2006
Marked heterogeneity of endothelin-mediated
contractility and contraction dynamics in mouse renal and femoral
arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp
Biol Med (Maywood) 231,
777-781, 2006
Postural effects on interstitial fluid pressure in
humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K.
Franzeck
J
Vasc Res 43,
321-326, 2006
2005
Ageing as a determinant of renal and vascular
disease: role of endothelial factors
M. Barton
Nephrol
Dial Transplant 20,
485-490, 2005
Anatomically distinct activation of endothelin-3 and
the L-arginine/nitric oxide pathway in the kidney with advanced
aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M.
Barton
Biochem
Biophys Res Commun 327,
234-241, 2005
Ageing as a determinant of renal and vascular
disease: role of endothelial factors
M. Barton
Nephrol
Dial Transplant 20,
485-490, 2005
Aging and biomedicine 2005: Where should we go from
here?
M. Barton
Cardiovasc
Res 66,
187-189, 2005
Vascular consequences of menopause and hormone
therapy: Importance of timing of treatment and type of
estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc
Res 66
, 295- 306, 2005
Endothelin inhibition delays onset of hyperglycemia
and associated vascular injury in type I diabetes: evidence
for endothelin release by pancreatic islet
β-cells.
J. Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R.
Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M.
Barton
Biochem
Biophys Res Commun 334,
689-695, 2005
Native and oxidized low-density lipoproteins
stimulate endothelin-converting enzyme-1 expression in human
endothelial cells
B. Niemann, S. Rohrbach, R.A. Catar, G. Muller, M. Barton, H.
Morawietz
Biochem
Biophys Res Commun 334,
747-753, 2005
Endothelin in the
microvasculature
M. Barton
In:
Microvascular Research: Biology and Pathobiology
(D.
Shepro, Ed.), Academic
Press,
San Diego, 5-12,
2005
Activation of pro-inflammatory and anti-inflammatory
cytokines in host organs during chronic allograft rejection:
role of endothelin receptor signaling
T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, D.G.
Souza, E. Haas, L. Tornillo, K. Münter, W. Vetter, M.
Barton
Am
J Transplant 5,
1042-1049, 2005
Management and prevention of obesity-related
hypertension
M. Barton
Renin
Angiotensin System in Cardiovascular Medicine
1,
11-13, 2005
2004
Role of podocytes for reversal of glomerulosclerosis
and proteinuria in the aging kidney after endothelin
inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N.
Parekh, T. Traupe, M. Lange, T. Lattmann, M.
Barton
Hypertension
44,
974-981, 2004
Protective Role of ETA
endothelin receptors during the acute phase of
Trypanosoma cruzi infection in rats
E.R.S. Camargos, L.L.V. Rocha, M.A. Rachid, A.P. Almeida, A.J.
Ferreira, A.L. Teixeira-Jr, E. Chiari,
M. Barton, M.M. Teixeira, C.R.S. Machado
Microbes
Infect 6,
650-656, 2004
Amiodarone acutely inhibits vascular activity of
endothelin-converting enzymes
T. Traupe, M. Lang, J. Ortmann, M. Keller, E. Fojtu, W. Vetter, M.
Barton
J
Cardiovasc Pharmacol 44,
S113-S116, 2004
Upregulation of vascular ETB
receptor gene expression after chronic
ETA
receptor blockade in prediabetic NOD
mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M.
Lange, W. Vetter, M. Barton
J
Cardiovasc Pharmacol 44,
S105-S108, 2004
In-vivo interactions of nitric oxide and
endothelin
T. Lattmann, W. Vetter, M. Barton
J
Hypertens 22,
1839-1840, 2004
Protease-activated receptors and EDHF: the icing on
the cake?
T. Traupe and M. Barton
Cardiovasc
Res 61,
645-647, 2004
Einfluss Postmenopausaler Hormonsubstitution mit
konjugierten equinen Oestrogenen
und Medroxyprogesteronazetat auf das kardiovaskuläre
Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz
Rundsch Med Prax 93,
904-914, 2004
2003
Lovastatin stimulates human vascular smooth muscle
cell expression of bone morphogenetic protein-2,
a potent inhibitor of low-density lipoprotein-stimulated cell
growth
L. Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M.
Barton
Biochem
Biophys Res Commun 302,
67-72, 2003
Obesity-associated activation of angiotensin and
endothelin in the cardiovascular system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T.
Traupe
Int
J Biochem Cell Biol 35,
826-837, 2003
Cardiovascular consequences of the obesity pandemic:
need for action
M. Barton, J. Furrer
Exp
Opin Invest Drugs 12,
1757-1759, 2003
Endothelin, hypercholesterolemia and
atherosclerosis
M.
Barton, T. Traupe, C.C. Haudenschild
Coron
Artery Dis 14,
477-490, 2003
Endothelial therapy of atherosclerosis and its risk
factors
T. Traupe, J. Ortmann, K. Münter, M. Barton
Current
Vasc Pharmacol 1,
111-121, 2003
2002
Obesity increases prostanoid-mediated
vasoconstriction and vascular thromboxane receptor gene
expression
T. Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W.
Vetter, M. Barton
J
Hypertens 20,
2239-2245, 2002
Acute effects of 17β-oestradiol on functional
activity of endothelin-converting enzymes in human arteries and
veins
A. Heigl, M. Lachat, T. Lattmann, T. Lüscher, M.
Barton
Clin
Sci (Lond) 103(S),
438S-441S, 2002
Estrogen and apoptosis in
atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future,
Samioe G, Skouby S, (Eds.). Proceedings of the
5th European Congress on Menopause, Copenhagen, Denmark, July 1-5,
2000
Elsevier
International Congress Series,
81-93, 2002
Postmenopausal hormone-replacement
therapy
M. Barton, R.K. Dubey
New
Engl J Med 346,
63-65, 2002
Effects of obesity on endothelium-dependent
reactivity during acute nitric oxide inhibition: modulatory role of
endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M.
Barton
Clin
Sci (Lond) 103
(Suppl. 48), 13S-15S, 2002
Role of endothelin during experimental Trypanosoma
cruzi infection in rats
E.R.S. Camargos, C.R.S. Machado, A.L. Teixeira-Jr, L.L.V. Rocha,
A.J. Ferreira, A.P. Almeida, M. Barton,
M.M.Teixeira
Clin
Sci (Lond) 103(S),
64S-67S, 2002
Increased expression of endothelin-converting
enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim,
H.-R. Zerkowski, J. Holtz
Clin
Sci (Lond) 103(S),
237S-240S, 2002
Chronic ETA
receptor blockade prevents endothelial dysfunction
of small arteries in apolipoprotein E-deficient
mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
Cardiovasc
Res 53,
487-495, 2002
Native LDL induces proliferation of human vascular
smooth muscle cells via a redox-mediated activation of ERK1/2
mitogen-activated protein kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension
39
(Part 2), 645-50, 2002
Green tea polyphenols inhibit human vascular smooth
muscle cell proliferation stimulated by native low-density
lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M.
Barton
Eur
J Pharmacol 434,
1-7, 2002
Oral contraceptives and the risk of thrombosis and
atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp
Opin Invest Drugs 11,
329-332, 2002
Chronic ETA
receptor blockade prevents endothelial dysfunction
of small arteries in apolipoprotein E-deficient
mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
Cardiovasc
Res 53,
487-495, 2002
Angiotensin-converting enzyme inhibitor therapy
prevents upregulation of endothelin-converting enzyme-1 in failing
human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim,
H.-R. Zerkowski, J. Holtz
Biochem
Biophys Res Commun 295,
1057-61, 2002
Acute effects of 17β-oestradiol on functional
activity of endothelin-converting enzymes in human arteries and
veins
A. Heigl, M. Lachat, T. Lattmann, T. Lüscher, M.
Barton
Clin
Sci (Lond) 103(S),
438S-441S, 2002
2001
Postmenopausal estrogen replacement therapy and
atherosclerosis: Can current compounds provide cardiovascular
protection?
M.
Barton
Exp
Opin Invest Drugs 20,
789-809, 2001
Endothelin receptor blockade and nitric oxide
bioactivity
M. Barton, B. Glodny
Cardiovasc
Res 52,
161-163, 2001
The therapeutic potential of endothelin receptor
antagonists in cardiovascular disease
M. Barton, W. Kiowski
Curr
Hypertens Rep 3,
322-330, 2001
Endothelin and cardiac arrhythmias: do endothelin
antagonists have therapeutic potential as antiarrhythmic
drugs?
F. Duru, M. Barton, T.F. Lüscher, R. Candinas
Cardiovasc
Res 49,
272-280, 2001
Increased expression of endothelin-1 and inducible
nitric oxide synthase isoform II in aging arteries in vivo.
Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K.
Münter, S.P. Müller, S. Shaw, M. Barton
Biochem
Biophys Res Commun 280,
908-13, 2001
Endothelium and atherogenesis: endothelial therapy
revisited
M. Barton, C.C. Haudenschild
J
Cardiovasc Pharmacol 38
(Suppl. 2), S23-S25, 2001
Increased expression of endothelin-1 and inducible nitric oxide
synthase isoform II in aging arteries in vivo. Implications for
atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K.
Münter, S.P. Müller, S. Shaw, M. Barton
Biochem
Biophys Res Commun 280,
908-13, 2001
2000
Obesity is associated with tissue-specific
activation of renal angiotensin-converting enzyme in vivo.
Evidence for a regulatory role of endothelin
M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H.
Hillen, C.C. Haudenschild,
J.E. Krieger, K. Münter, T. Lattmann, T.F. Lüscher, S.
ShawHypertension
35,
329-336, 2000
Endothelin and endothelin antagonists. Therapeutic
considerations for a novel class of cardiovascular
drugs
T.F. Lüscher, M. Barton
Circulation
102,
2434-2440, 2000
Dysfunctional renal nitric oxide synthase as a
determinant of salt-sensitive hypertension: mechanisms
of renal artery dysfunction and role of endothelin for vascular
hypertrophy and glomerulosclerosis
M. Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne,
T.J. Rabelink, T. Lattmann, P. Moreau, T.F.
Lüscher
J
Am Soc Nephrol 11,
835-846, 2000
Oestrogensubstitutionstherapie und Arteriosklerose -
Pathophysiologie und therapeutische
Implikationen
M. Barton
J
Menopause 7,
12-15, 2000
Hypertension, diabetes mellitus,
hypercholesterolemia and endothelin B receptor-mediated renal
nitric oxide release
M. Barton, L.V. d'Uscio
Circulation
101;
e228-e229, 2000
Sex and NO - beyond regulation of vasomotor
tone
M. Barton
Cardiovasc
Res 46,
20-23, 2000
Assessment of coronary flow reserve by
contrast-enhanced second harmonic echo
Doppler
R. Jenni, A. Linka, M. Barton
Circulation
101,
e100, 2000
Deloading of the left ventricle by ventricular
assist device normalizes increased expression of endothelin
ETA
receptors
but not endothelin-converting enzyme-1 in patients with end-stage
heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S.
Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation
102,
III188 -III193, 2000
Doppler mirror image artifacts mimicking mitral
regurgitation in patients with mechanical bileaflet mitral valve
prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R.
Jenni
Eur
J Echocardiography 1,
138-43, 2000
Ventricular arrhythmias induced by endothelin-1 or
by acute ischemia: a comparative analysis using three dimensional
mapping
F. Duru, M. Barton, R. Candinas
Cardiovasc
Res 46,
604-605, 2000
Receptor- and non-receptor-mediated clearance of
big-endothelin and endothelin-1: differential effects of acute and
chronic ETA
receptor blockade
M. Burkhardt, M. Barton, S.G. Shaw
J
Hypertens 18,
273-279, 2000
Endothelial dysfunction and atherosclerosis:
endothelin receptor antagonists as novel
therapeutics
M. Barton
Curr
Hypertens Reports 2,
84-91, 2000
Endothelin
und Atherosklerose. Kausale Bedeutung und therapeutische
Implikationen
M. Barton
Kardiovask
Med 3,
13-18, 2000
Endothelin in atherosclerosis: importance of risk
factors and therapeutic implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
J
Cardiovasc Pharmacol 35
(4 suppl 2), S55-S59, 2000
Inverse regulation of endothelin-1 and nitric oxide
metabolites in tissue with aging: implications
for the age-dependent increase of cardiorenal
disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Lüscher, S.
Shaw
J
Cardiovasc Pharmacol 36
(Suppl.1), S153-S156, 2000
Endothelin regulates angiotensin-converting enzyme
in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz,
L.V. d'Uscio, T. Lattmann, T.F. Lüscher, S. Shaw
J
Cardiovasc Pharmacol 36
(Suppl.1), S244-S247, 2000
1999
Endothelin antagonists for hypertension and renal
disease
M. Barton, T.F. Lüscher
Curr
Opin Nephrol Hypertens 8,
549-556, 1999
Endothelial dysfunction in acute renal faiulre: role
of circulating and tissue endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F.
Luscher
J
Am Soc Nephrol 10,
953-962, 1999
Endothelial dysfunction in the aorta of transgenic
rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F.
Lüscher
Endothelium
6,
175-184, 1999
Estrogen and vascular
resistance
M. Barton, T.F. Lüscher
Curr
Opin Endocrinol Diabet 6,
218-224, 1999
Vascular effects of estrogens: rapid actions, novel
mechanisms, and potential therapeutic
implications
M. Barton
Acta
Pharmacol Sin 20,
682-690, 1999
Endothelin in heart failure
G. Sutsch, M. Barton
Curr
Hypertens Reports 1,
62-68, 1999
Vascular
effect of estrogen
E.
Wight, M. Barton, E. Espinosa, T. Luscher.
In:
Menopause and the Heart (T.B.
Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia; 1,
1-7, 1999
1998
Endothelin ETA
receptor blockade restores NO-mediated endothelial
function and inhibits atherosclerosis in apolipoprotein E-deficient
mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter,
T.F. Lüscher
Proc
Natl Acad Sci U.S.A. 95,
14367-14372, 1998
ETA
receptor blockade prevents increased tissue
endothelin-1, vascular hypertrophy, and endothelial
dysfunction
in salt-sensitive hypertension
M. Barton, L.V. d`Uscio, S. Shaw, P. Meyer, P. Moreau, and T.F.
Lüscher
Hypertension
31,
499-504, 1998
Losartan but not verapamil inhibits angiotensin
II-induced tissue endothelin-1 increase. Role of blood
pressure
and endothelial function
L.V. d`Uscio, S. Shaw, M. Barton, T.F. Lüscher
Hypertension
31,
1305-1310, 1998
Endothelial
aging. A determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and
Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July
23-24, 1998
Cardiovasc
Drug Rev 3,
300-311, 1998
Salt Wars
M. Barton, T.F. Lüscher, T.J. Rabelink
Science 281,
1961, 1998
Endothelial vasoconstrictor prostanoids, vascular
reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller,
T.F. Lüscher
Kidney
Int 67,
S199-S201, 1998
Differential modulation of the renal myocardial
endothelin system by angiotensin II in vivo:
effects of chronic selective ETA
receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F.
Lüscher
J
Cardiovasc Pharmacol 31
(Suppl 1), S265-S268, 1998
17β-Estradiol acutely improves endothelium-dependent
relaxation to bradykinin in isolated human coronary
arteries
M. Barton, J. Cremer, A. Mügge
Eur
J Pharmacol 362,
73-76, 1998
Endothelium-independent relaxation and
hyperpolarization to C-type natriuretic peptide in porcine coronary
arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F.
Lüscher
J
Cardiovasc Pharmacol 31,
377-383, 1998
1997
Biology of the endothelium
T.F. Lüscher, M. Barton
Clin
Cardiol 20
(Suppl. II), 3-10, 1997
Angiotensin II increases vascular and renal
endothelin-1 and functional endothelin converting enzyme activity
in vivo:
role of ETA
receptors for endothelin
regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F.
Lüscher
Biochem
Biophys Res Commun 238,
861-865, 1997
Anatomic heterogeneity of vascular aging. Role of
nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F.
Lüscher
Hypertension
30,
817-824, 1997
Structure and function of small arteries in
salt-induced hypertension: effects of chronic
endothelin-subtype-A-receptor blockade
L.V. d'Uscio, M. Barton, S. Shaw, P. Moreau, T.F.
Lüscher
Hypertension
30,
905-911, 1997
Angiotensin II increases tissue endothelin and
induces vascular hypertrophy: reversal by ETA-receptor antagonist
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, T.F.
Lüscher
Circulation
96,
1593-1597, 1997
Effects of chronic ETA-receptor blockade in angiotensin II-induced
hypertension
L.V. d`Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, T.F.
Lüscher
Hypertension
29,
435-441, 1997
Endothelial-derived superoxide anions in pig
coronary arteries: evidence from lucigenin chemiluminescence
and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A.
Mügge
J
Physiol (Lond) 500,
331-342, 1997
The
endothelium as therapeutic target for atherosclerosis. Importance
of ACE inhibition and cholesterol lowering
M. Barton, T.F. Lüscher
Thoraxcenter J 9,
12-19, 1997
Anatomic heterogeneity of vascular aging. Role of
nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F.
Lüscher
Hypertension
30,
817-824, 1997
Contractile responses to histamine, serotonin, and
angiotensin II are impaired by 17β-estradiol
in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology
54,
162-168, 1997
Gefässprotektion durch Oestrogene. Wirkungen in
vitro und in vivo - Mechanismen und klinische
Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F.
Lüscher
Schweiz
Rundsch Med (PRAXIS) 86,
129-137, 1997
1996
17β-Oestradiol inhibits growth of human vascular
smooth muscle: similar effects in cells from females and
males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F.
Lüscher
J
Cardiovasc Pharmacol 28
(Suppl. 5), S34-S39, 1996
Wirkungen natürlicher Oestrogene auf die Gefässwand:
Molekulare Mechanismen und klinische
Implikationen
T.F. Lüscher, M. Barton, E. Wight, E. Espinosa, Z.
Yang
Schweiz
Med Wschr 126,
1748-1755, 1996
Effect of age on kinetics of nitric oxide release in
rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino,
G. Noll, T. Malinski, T.F. Lüscher
J
Clin Invest 98,
899-905, 1996
1993
Different vascular reactivity of human internal
mammary and inferior epigastric arteries in
vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R.
Lichtlen
Ann
Thorac Surg 56,
1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol
of human coronary arteries in vitro
A.
Mügge, M. Riedel, M. Barton, M. Kuhn, P.R.
Lichtlen
Cardiovasc
Res 27,
1939-1942, 1993